According to many observations, certain virus infections may play a part in the autoimmune attack that leads to type 1 diabetes. Researchers have now produced a vaccine for these viruses in the hope that it could provide protection against the disease.

Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists.

As interest in the application of plasma medicine -- the use of low-temperature plasma (LTP) created by an electrical discharge to address medical problems -- continues to grow, so does the need for research advancements proving its capabilities and potential impacts on the health care industry. Across the world, many research groups are investigating plasma medicine for applications including cancer treatment and the accelerated healing of chronic wounds, among others.

Moderna Inc and Swiss contract drugmaker Lonza Group AG said on Friday they would accelerate the manufacturing of the U.S. drug developer's potential coronavirus vaccine.

The following is a brief roundup of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

The following is a brief roundup of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Pfizer Inc said on Friday it is in talks to shift more of its medicine production to outside contractors as it prepares for large-scale production of an experimental vaccine to prevent COVID-19, should it prove safe and effective.

Read our live coronavirus updates HERE Coronavirus: the symptoms

Read our live updates on coronavirus HERE Coronavirus: The symptoms

Follow our live updates here Coronavirus: the symptoms

A task force has been set up in the UK to accelerate the development of a coronavirus vaccine.

The number of deaths linked to coronavirus across the world has hit 150,000, with the UK reporting 14,576 in hospitals alone.

Coronavirus: The symptoms

A team of scientists are due to start clinical trials towards the end of next week

The Government's chief scientific adviser has warned that coronavirus vaccines are "long shots" after human trials are set to begin within the next seven days.

Trials of a vaccine that could protect against Covid-19 are to begin in the UK.

Human trials of a potential coronavirus vaccine being developed at the University of Oxford will begin on Thursday, Health Secretary Matt Hancock said.

Read our live updates below...

Teams at Imperial and Oxford appeal to Londoners to join Covid-19 fight

A coronavirus vaccine is unlikely to be available before the year is out despite tens of millions of pounds being spent on UK trials that start imminently.

The first people have been injected as the UK starts human trials for a coronavirus vaccine.

The success of the Government's shutdown measures to curb the spread of Covid-19 may hamper the process of gathering data to develop a vaccine, a scientist leading clinical trials has said.

A coronavirus vaccine might not be ready until later next year, the former deputy chief medical officer for England has said.

A doctor who became one of the first people in Europe to receive a potential coronavirus vaccine says she is "doing fine" after rumours claimed she had died.

A potential coronavirus vaccine being trialled by UK researchers will be rapidly produced in vast numbers if it proves effective.

The family of a four-year-old boy with a rare form of cancer is raising money to take him to New York for a potentially life-saving vaccine.

Some social distancing measures will remain in place until a coronavirus vaccine has been developed, Michael Gove has said.

Brits may have to accept a "new normal" with social distancing measures remaining in place until a vaccine is available, Michael Gove has suggested.

Donald Trump has claimed a coronavirus vaccine will be developed "by the end of this year".

Boris Johnson has asked Vladimir Putin if Russia would help play a more integrated role in global efforts to develop a coronavirus vaccine.

Bill Gates has been big on vaccines since before the start of the coronavirus pandemic, but in a new blog posting, the Microsoft co-founder and billionaire philanthropist says the only way to end the pandemic for good is to offer a vaccine to almost all of the planet's 7 billion inhabitants. That's big. "We've never delivered something to every corner of the world before," Gates notes. It's especially big considering that a vaccine hasn't yet been approved for widespread use, and that it may take as long as a year to 18 months to win approval and start distribution. Some… Read More

‘Challenge’ studies would deliberately give coronavirus to healthy volunteers

• Coronavirus – latest updates
• See all our coronavirus coverage

Controversial trials in which volunteers are intentionally infected with Covid-19 could accelerate vaccine development, according to the World Health Organization, which has released new guidance on how the approach could be ethically justified despite the potential dangers for participants.

So-called challenge trials are a mainstream approach in vaccine development and have been used in malaria, typhoid and flu, but there are treatments available for these diseases if a volunteer becomes severely ill. For Covid-19, a safe dose of the virus has not been established and there are no failsafe treatments if things go wrong.

More than 500 people enrol to test jab following trials in animals

'Nothing like waking up to a fake article on your death,' tweets Elisa Granato

1. Inactivated PiCoVacc vaccine found safe, efficacious in animal study  The Hindu
2. China conducts first successful coronavirus vaccine test on monkeys  Times of India
3. COVID-19 vaccine test on animals successful | Under test since mid-April  WION
4. Promising coronavirus vaccine candidate from China in talks to be tested globally  Times Now
5. US may suffer major blow if China produces vaccine against Covid-19 first  Hindustan Times
6. View Full coverage on Google News

While the lockdown continues across the UK - streaming giants Amazon Prime, Disney+ and Netflix have added a number of new movies which were originally due to premiere in cinemas.

Directed By:Christopher Nolan Starring:John David Washington, Robert Pattinson, Elizabeth Debicki, Dimple Kapadia, Aaron Taylor-Johnson, Clémence Poésy, with Michael Caine and Kenneth Branagh. TENET will be released nationwide on 17th July 2020 by Warner Bros. Pictures

The post TENET – In cinemas 17th July 2020 appeared first on UKFilmNews.com.

ICMR teams up with Bharat Biotech to make vaccineThe vaccine will be developed using the virus strain isolated at the ICMR's National Institute of Virology (NIV), Pune, a statement said. The strain has been successfully transferred from NIV to BBIL, it added. The death toll due to COVID-19 rose to 1,981 and the number of cases climbed to 59,662 in the country on Saturday, according to the Union Health Ministry.

Follow our live coronavirus updates here

There are many challenges to developing a vaccine that will be successful against COVID-19.eamesBot / Shutterstock

Wayne Koff is one of the world’s experts on vaccine development, the president and CEO of the Human Vaccines Project. He possesses a deep understanding of the opportunities and challenges along the road to a safe and effective vaccine against COVID-19. He has won prestigious awards, published dozens of scientific papers, held major positions in academia, government, industry, and nonprofit organizations. But Koff, 67, has never produced a successful vaccine.

“I have been an abject failure,” he says. He smiles with a charming, self-deprecating sense of humor. “That’s what the message is.”

The real reason for Koff’s lack of success is that he spent most of his career searching for a vaccine against HIV, the virus that causes AIDS. It remains, as he and many others put it, “the perfect storm” of a viral infection resistant to a vaccine development. Almost 40 years after doctors first recognized the disease in five men in Los Angeles—and 70 million people have been infected worldwide—there are no adequate animal models. Neutralizing antibodies, the backbone of many vaccines, do not stop it, and most importantly, HIV begins its assault on the body by attacking CD4 T cells, which serve as the command center of much of the immune system.

As for COVID-19, “We’re all hoping this one is going to be easier,” says Koff, a slight, bearded man with thick, curly salt-and-pepper hair. “There are research issues that still have to be addressed on a COVID vaccine. But they are a lot more straightforward than what we were dealing with in HIV.”

Let’s say we have a vaccine in 18 months. How do you make 1 billion doses or 4 billion doses or whatever it’s going to take to immunize everybody?

Koff and others started the Human Vaccines Project in 2016, modeled on the Human Genome Project. The project works with industry and academia to study the human immune system and develop vaccines, incorporating every modern-day tool, including artificial intelligence, computational biology, and big data sets. Today it is partnered with the Harvard T.H. Chan School of Public Health.

With COVID-19, Koff says, scientists “know the target is the spike protein binding site.” This is where the proteins sticking out from the virus attach to the cells in the human respiratory system. “If you can elicit antibodies against those proteins, they should be neutralizing.” He puts a strong emphasis on should. To prove antibodies will prevent infection, scientists must watch a population of people who’ve been infected for months or longer. It’s a good bet, based on similar viruses, that antibodies will appear and protect—although no one right now can predict how long and how well.

Depending on which count you use, more than 70 companies, universities, and other institutions are offering candidate vaccines. Koff says the real number of companies is lower. During the AIDS crisis, he says, “a lot of people claimed they had an experimental HIV vaccine in development. Some of those were a one-person lab who had created a paper company to attract investors.”

But even with a lower number, almost everyone involved in the search for a vaccine agrees that several different approaches from different research organizations need to proceed in parallel. The world does not have the time to bet on one horse. The race will be neither simple nor cheap.

“The probability of success, depending on whose metric is used in vaccines, is somewhere between 6 and 10 percent of candidate vaccines that make it from the animal model through licensure,” Koff says. “That process costs $1 billion or more. So you can do the math.”

Koff sees big potential problems at the outset. “In the best of all worlds, let’s say we have a vaccine in 18 months. Who knows where the epidemic is going to be then and what its impact is going to be? How do you make 1 billion doses or 4 billion doses or whatever it’s going to take to immunize everybody? Will we need one dose or two or three? These are issues people just haven’t faced before.”

COVID-19 also presents some unique dangers for vaccine safety. Based on how the virus behaves when it infects some people, there’s a chance a vaccine could dangerously overstimulate the immune system, a reaction called immune enhancement. “I’m hoping it’s more theoretical than real,” Koff says. “But that has to be addressed and it may slow down the entire process.” To ensure safety, he says, “It may mean we have to test the vaccine in a larger number of people. It’s one thing to do a 50-person trial in healthy adults as a safety signal. It’s another thing to run a trial of 4,000 or 5000 or more individuals.”

The world does not have the time to bet on one horse. The race will be neither simple nor cheap.

A virus also sometimes causes mysterious, potentially deadly blood clots. This means an experimental vaccine could hypothetically induce the same damage. “This is a bad bug,” Koff says. “We’re just starting to understand that pathogenesis.”

A big question is who should be the first volunteers for widespread vaccine testing. “Who are the high-risk groups?” asks Koff. “Is it nursing-home residents and staff, health-care workers and people on the front lines, or people someplace else like grocery stores? We must also make sure a vaccine is effective for the elderly and people in the developing world.”

Many vaccines work well in young and healthy people but not in older adults because immunity declines with age. Influenza vaccine is a prime example. Rotavirus vaccine, which protects against the deadliest killer—diarrheal disease in children—works better in the developed world. In the developing world, the virus often circulates year-round. Infants get antibodies from breast milk but not enough to prevent disease. Worse, those antibodies can make the vaccine less effective.

Another hypothetical obstacle is that a mutation in the COVID-19 virus could render a vaccine designed today less effective in the future. While the virus mutates frequently, so far there has been little change in the critical part of the spike that binds to human cells.

Of course, neither Koff nor all the others working for a COVID-19 vaccine focus solely on the potential obstacles. At one time, all vaccines against viruses either killed viruses, such as the Salk polio vaccine, or rendered them harmless, such as the Sabin polio vaccine. Now there is a multiplicity of ways to stimulate an immune response to prevent infection or reduce the consequences. These include genetically engineered protein subunits (peptides) or virus-like particles. Such approaches have led to successful vaccines against hepatitis B and human papilloma virus, which causes cervical cancer. Researchers now use “vectors”—harmless viruses attached to the protein subunits and virus particles to transmit them into the body. There are also many new adjuvants, chemicals that boost immune response to a vaccine.

Newer platforms include direct injection of messenger-RNA. M-RNA is the chemical used to translate the information in DNA into proteins in all cells. The Moderna Company, which received a $483 million grant from the U.S. government, and has begun early clinical trials, uses m-RNA to try to make the body produce proteins to protect against the COVID-19 virus. INOVIO Pharmaceuticals uses pieces of DNA called plasmids to achieve the same objective. It has also begun phase 1 studies.

“There are about eight platforms, and it would be good to see a couple vaccines in each of those advance,” Koff says. Predicting which of these most likely to succeed or fail he says would be “simply foolish.”

Many groups, including the Human Vaccines Initiative, are plotting routes to test any possible vaccine more quickly than tradition dictates with an “adaptive trial design.” Usually trials begin with a phase 1 study of some 50 healthy people to search for any immediate signs of toxicity, then moves onto about 200 people in a phase 2, still looking for hazards and a signal of immunity, and then to phase 3 in thousands of people. But the plan here is to start phases 2 and 3 even before its predecessors are finished, and keep recruiting additional volunteers so long as no danger signals arise.

Good animal models are appearing almost daily. Macaque monkeys, hamsters, and genetically engineered mice have all been infected in the laboratory and could determine whether potential vaccines exhibit various types of immunity. Members of Congress from both sides of the aisle have suggested that healthy human volunteers should be allowed to agree to be test subjects, allowing themselves to be infected. Stanley Plotkin, a vaccine researcher at the University of Pennsylvania, was among the first to suggest the idea.

Arthur Caplan, a bioethicist at New York University, says that “deliberately causing disease in humans is normally abhorrent.” But COVID-19 is anything but a normal circumstance. In this case, Caplan says, “asking volunteers to take risks without pressure or coercion is not exploitation but benefitting from altruism.” At least 1,500 people have already volunteered to be such human guinea pigs, although none of the experimental vaccines is far enough along to try such challenging experiments.

Koff says the key to a successful vaccine is a cooperative effort. “It’s going to take a whole different way of thinking to move this onto the expedited train,” he says. “The old dog-eat-dog, ‘I’m going to beat you to the end of the game,’ isn’t going to help us with this.” Seth Berkley, who worked with Koff at the International AIDS Vaccine Initiative, and now heads GAVI, an international vaccine organization, agrees that a COVID-19 vaccine needs a Manhattan Project approach. “An initiative of this scale won’t be easy,” Berkley says. “Extraordinary sharing of information and resources will be critical, including data on the virus, the various vaccine candidates, vaccine adjuvants, cell lines, and manufacturing advances.”

Koff has no regrets about spending so many years on an AIDS vaccine without results. He learned a great deal, he says, which he’s putting to work in the COVID-19 crisis. “The reason COVID-19 vaccines should be a lot easier is because most of the platforms, the novel approaches, and the clinical infrastructure for the testing of vaccines, came out of HIV.” He pauses. “We’re far better prepared.”

Robert Bazell is an adjunct professor of molecular, cellular, and developmental biology at Yale. For 38 years, he was chief science correspondent for NBC News.

The expectation is the U.S. won’t return to normal until there’s an effective vaccine against COVID-19  — and almost everyone in the country has been vaccinated.

Thousands of people have volunteered to be exposed to coronavirus if it means a vaccine can be developed more quickly. Should we let them?

President Trump on Friday broke with health experts, telling reporters that the coronavirus will “go away without a vaccine.”

The iconic Italian properties have joined forces to help end the Coronavirus crisis

Today marks the start of human drug trials, as beating Covid-19 becomes a global effort. Susannah Butter reports

The Thor star was thankful to finally be on a well-deserved break from his hectic schedule.

Nicola Sturgeon has warned Scottish football fans they should have no "false expectations" of attending matches in the near future, also stressing the dangers of behind-closed-doors events.

West Ham midfielder Manuel Lanzini believes it would be "crazy" for the Premier League to resume playing while coronavirus remains a threat to player safety.

While researchers across Canada are among the scientists working on coronavirus vaccines, the country doesn’t have the means to quickly produce any successful result.

The Office of the Special Counsel is recommending that Bright be temporarily reinstated.